Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:2/16/2010

REOLYSIN

REOLYSIN is a proprietary formulation of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the MHRA's approval of a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... On behalf of biotech client GenScript ... Goldman & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript,s ... judgment notwithstanding the verdict, a new trial, and remittitur. ...
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 RURO, Inc., ... released FreezerPro® version 6.2 – the latest update to ... reputation is that of a quick and easy method ... With the latest version, RURO engineering has enhanced the ... to move large amounts of sample records. , ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2
... Science ... ... -- DuPont was named the 2009 recipient of the Corporate Innovation Award by the ... that has made a substantial difference in the marketplace and global community., , , ...
... experiment by college students that will study how microbes grow ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , ... developed the experiment that will fly as part of the ... p.m. EST on Nov. 16 from NASA,s Kennedy Space Center ...
... 12 Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH ), ... I/II open-label dose-ranging trial with Apoptone® (HE3235) for hormone-resistant ... on November 16 at the American Association for Cancer ... Boston. Apoptone, a novel steroid that is an ...
Cached Biology Technology:DuPont Receives Corporate Innovation Award 2DuPont Receives Corporate Innovation Award 3DuPont Receives Corporate Innovation Award 4Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 2Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 3Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 4Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference 5
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... immune system's pro-inflammatory response to bacterial invasion is ... called inducible nitric oxide synthase. In a study ... report that the predominantly anti-inflammatory enzyme, endothelial nitric ... production in response to infection. This discovery may ...
... Until now it has been impossible to accurately measure ... in real time and at the level of a ... Plant Biology and Stanford University are the first to ... molecular sensors to view changes in brain chemical levels. ...
... (MGH) has identified 80 new genes essential to the ... tool for inactivating genes in plants or animals. They ... that participate in the gene-silencing mechanism, which someday may ... in the journal Science and is receiving early online ...
Cached Biology News:Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Revolutionary nanotechnology illuminates brain cells at work 2Revolutionary nanotechnology illuminates brain cells at work 3Scientists identify genetic pathways essential to RNA interference 2Scientists identify genetic pathways essential to RNA interference 3
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
F40 piston seals are supplied as 2 seals with a seal tool to service one F40 pump of a BioLogic DuoFlow workstation....
... probe for DNA. Binds to the minor ... rich DNA), forming a stable complex which ... alone. DAPI is several times more sensitive ... agarose gels. It may be used for ...
Mol wt: monoisotopic mol wt1,045.5423 Da by calculation...
Biology Products: